Zoetis Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹32.8K Cr
- Zoetis projects full-year 2026 revenue growth of 2% to 5% based on the current operating environment. - Zoetis updated full-year 2026 revenue guidance to $9.68 billion - $9.96 billion, representing 2% to 5% growth, reflecting current operating environment with macro and competitive challenges.
From Zoetis Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹78.27
Market Cap
₹32.8K Cr
P/E Ratio
13.2
Revenue Rank
Margin Rank
How does Zoetis Inc. rank in Pharmaceuticals?
Compare Zoetis Inc. against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 4- →Zoetis projects full-year 2026 revenue growth of 2% to 5% based on the current operating environment.
- →Livestock segment expected to drive momentum with mid- to high single-digit growth for the year.
- →Companion animal growth anticipated but at a slower pace than livestock; international companion animal sales grew 7% this quarter.
- →The company is focused on expanding markets to counteract competitive and macroeconomic pressures, particularly in parasiticides and OA Pain areas.
- →Expected challenges include ongoing macroeconomic price sensitivity, competitive intensity, and lower vet clinic visit volumes.
- →Innovation and pipeline products, including long-acting Cytopoint and new launches in renal and oncology markets, are critical to returning to growth.
- →Management remains confident in the long-term structural demand for veterinary care and plans to sharpen commercial execution and cost discipline to drive growth.
📈 Profitability & Margins
Rank 3- →Zoetis updated full-year 2026 revenue guidance to $9.68 billion - $9.96 billion, representing 2% to 5% growth, reflecting current operating environment with macro and competitive challenges.
- →Adjusted net income guidance is $2.87 billion - $2.95 billion, growing 2% to 6%, supported by cost and productivity programs.
- →Adjusted diluted EPS expected in the range of $6.85 to $7.00, with reported diluted EPS $6.35 to $6.50.
- →Macro and competitive headwinds, especially in U.S. companion animal, persist with price sensitivity and lower clinic visits impacting near-term performance.
- →The company expects stabilization in market conditions and is focused on commercial execution and innovation pipeline for longer-term growth.
- →The 200-250 basis points revenue tailwind from fiscal calendar alignment in 2026 is a one-time benefit and will not recur in 2027.
- →Long-term outlook remains positive, with confidence in portfolio strength and innovation driving future growth beyond 2026.
🏗️ Capital Expenditure Plans
Yes- →Zoetis is actively investing in its business and innovation pipeline as a priority for capital allocation.
- →The company announced an agreement to acquire Neogen’s animal genomics business, expanding capabilities in livestock genetics—reflecting a targeted, strategic business development approach.
- →Investment focus includes scaling innovation, shortening time from approval to launch, and advancing convenience-led life cycle innovations (e.g., long-acting mAbs, Procerta, Convenia RTU).
- →There is an emphasis on driving procurement and operating efficiencies as part of a comprehensive cost and productivity program.
- →Zoetis continues investing in science to scale model and commercial execution to position for innovation-driven growth over time.
- →Capital allocation is sharpened to balance investment in key growth priorities with disciplined cost management to deliver long-term shareholder value.
💰 Fundraising & Capital Structure
No information- →There is no mention of any current or planned new fundraising through debt or equity in the provided excerpts.
- →The company emphasizes sharpening capital allocation and enhancing cost discipline.
- →Focus is on investing in key growth priorities and innovation rather than large transformational business development.
- →Zoetis highlights strategic, targeted business development like the Neogen acquisition but does not indicate raising capital through equity or debt.
- →The firm is committed to delivering long-term shareholder value primarily through operational execution and portfolio innovation.
📋 Order Book & Pipeline
NoKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
Frequently Asked Questions
What were Zoetis Inc. Q2 FY26 results?
- Zoetis projects full-year 2026 revenue growth of 2% to 5% based on the current operating environment. - Zoetis updated full-year 2026 revenue guidance to $9.68 billion - $9.96 billion, representing 2% to 5% growth, reflecting current operating environment with macro and competitive challenges.
What is Zoetis Inc. share price analysis?
Zoetis Inc. currently shows a neutral. The stock trades at a P/E of 13.2 with a market cap of $32,813. Investors should review the full earnings analysis for detailed insights.
Is Zoetis Inc. planning capital expenditure?
- Zoetis is actively investing in its business and innovation pipeline as a priority for capital allocation.
Keep Zoetis Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.